Brightfield Therapeutics leverages image-based machine learning to accelerate the future of cell therapy.
We engineer iPSCs for predictable, scalable differentiation into specific therapeutic lineages.
Our platform analyzes cell states in real time using brightfield microscopy and deep learning.
Brightfield microscopy + ML enables non-invasive identification of cell states and lineage potential.
Computer vision + robotics provide continuous monitoring and automated decision loops.
A software-first model enabling scalable deployment across cell therapy manufacturing partners.
Starting with well-characterized iPSC lines engineered for predictability.
Image-based models identify optimal differentiation routes and reduce batch variability.
Non-invasive phenotype monitoring supports regulatory alignment.
Embedded imaging enables automated lot release and consistent QC.
Join us in building image-based manufacturing for next‑generation cell therapies.
Build imaging classifiers and phenotype models.
Develop differentiation protocols using real-time imaging feedback.
Integrate robotics and microscopy into closed-loop systems.